Skip to Main Content
Diabetes Research Center
YSM Home

INFORMATION FOR

Headaches, Phase III

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

What is the purpose of this trial?

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.

  • Trial with
    Eli Lilly and Company
  • Ages
    6 years - 17 years
  • Gender
    Both
Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Erin Weidman

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

  • Last Updated
    03/06/2024
  • Study HIC
    #2000028716

Contact Information

For more information about this study, including how to volunteer, contact Erin Weidman